{"schema_version":"1","generated_at":"2026-11-08T13:01:13.630Z","data_as_of":"2026-11-08","url":"https://www.findmykol.com/kol/david-planchard","json_url":"https://www.findmykol.com/kol/david-planchard/profile.json","record_kind":"full","profile_kind":"research","person":{"slug":"david-planchard","name":"David Planchard","credential":"MD","title":"Thoracic oncologist, Gustave Roussy; Associate Professor, Université Paris-Saclay","specialty":"Medicine","therapeutic_area":"Lung","therapeutic_areas":["Lung"],"institution":"Gustave Roussy","institution_url":"https://www.findmykol.com/institution/gustave-roussy","country":{"name":"France","code":"FR","status":"provisional"},"register":{"label":"licensed_physician","kind":"rpps","id":"10002727849","country":"FR","specialty":"Pneumologie","hospital":"INSTITUT GUSTAVE ROUSSY SITE VILLE JUIF","as_of":"2026-10-19"}},"identifiers":{"orcid":"0000-0002-1565-8310","openalex":"A5028596081","rpps":"10002727849"},"summary":"David Planchard is Thoracic oncologist, Gustave Roussy; Associate Professor, Université Paris-Saclay at Gustave Roussy. OpenAlex indexes 749 publications with 52,197 citations (h-index 88); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.","overview":{"text":"David Planchard is Thoracic oncologist, Gustave Roussy. The public record shows 749 publications with 52,197 citations (h-index 88), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 9 registered clinical trials.","bullets":["Most recent indexed publication: 2026 · Clinical cancer research","Top research focus: Lung Cancer Treatments and Mutations","9 registered trials on ClinicalTrials.gov"],"generated_at":"2026-11-08"},"focus":{"indications":[{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":8,"topics":0,"strength":25},{"label":"Small Cell Lung Carcinoma","therapeutic_area":"Oncology","trials":8,"topics":0,"strength":24},{"label":"Melanoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Neoplasm Metastasis","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Brain Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"IBD (Crohn's / UC)","therapeutic_area":"Gastroenterology","trials":0,"topics":0,"strength":1},{"label":"Ovarian / Gynecologic Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Multiple Sclerosis","therapeutic_area":"Neurology","trials":0,"topics":0,"strength":1},{"label":"Gastroesophageal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Pancreatic Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Lupus (SLE)","therapeutic_area":"Rheumatology/Immunology","trials":0,"topics":0,"strength":1},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Head & Neck Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Tuberculosis","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Myasthenia Gravis","therapeutic_area":"Neurology","trials":0,"topics":0,"strength":1},{"label":"IBS / Functional GI","therapeutic_area":"Gastroenterology","trials":0,"topics":0,"strength":1},{"label":"Bladder / Urothelial Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"HIV","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1},{"label":"Idiopathic Pulmonary Fibrosis","therapeutic_area":"Respiratory","trials":0,"topics":0,"strength":1},{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Hepatobiliary Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Acromegaly","therapeutic_area":"Endocrinology/Metabolic","trials":0,"topics":0,"strength":1}],"research_topics":["Lung Cancer Treatments and Mutations","Lung Cancer Diagnosis and Treatment","Cancer Immunotherapy and Biomarkers","Lung Cancer Research Studies","Cancer Genomics and Diagnostics"],"drugs_studied":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"3-(3-Chloro-2-methoxyanilino)-7-(2-methoxyethyl)-2-(2-methylpyrimidin-4-yl)-1,5-dihydropyrrolo[3,2-c]pyridin-4-one","trials":1,"payments":0,"publications":0,"mentions":1}]},"works_with":{"total":5,"shown":3,"withheld":2,"rows":[{"name":"Gustave Roussy, Cancer Campus, Grand Paris","trials":2,"payments":0,"mentions":2},{"name":"Intergroupe Francophone de Cancerologie Thoracique","trials":2,"payments":0,"mentions":2},{"name":"Pierre Fabre Medicament","trials":2,"payments":0,"mentions":2}]}},"scholarship":{"works_count":749,"cited_by_count":52197,"h_index":88,"i10_index":288,"pubmed_count":19,"latest_activity_year":2026,"source":"works"},"trials":{"count":9,"shown":3,"withheld":6,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07431073","title":"Immunotherapy Master Trial for Advanced Cancers","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"UNICANCER","source_url":"https://clinicaltrials.gov/study/NCT07431073"},{"nct":"NCT07360743","title":"Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"UNICANCER","source_url":"https://clinicaltrials.gov/study/NCT07360743"},{"nct":"NCT06567015","title":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","phase":"PHASE1/PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"Pierre Fabre Medicament","source_url":"https://clinicaltrials.gov/study/NCT06567015","trial_url":"https://www.findmykol.com/trial/NCT06567015"}],"source":"trials"},"payments":{"note":"Not attributed. This person has no U.S. clinical registration (NPI) on file, so industry payments cannot be reliably tied to them."},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"congress":{"count":240,"years":{"first":2004,"last":2026},"societies":["AACR","ASCO","ASTRO","ESMO","IASLC","ISPOR Europe"],"shown":3,"withheld":237,"rows":[{"title":"Abstract 2434: Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-2434","source_url":"https://doi.org/10.1158/1538-7445.am2026-2434","status":"verified"},{"title":"Abstract 6472: Tumor-cell NY-ESO-1 expression predicts poor response to PD-1/PD-L1 blockade in NSCLC","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-6472","source_url":"https://doi.org/10.1158/1538-7445.am2026-6472","status":"verified"},{"title":"Abstract 7766: Single-dose neoadjuvant atezolizumab in resectable stage IA-IIIA non-N2 NSCLC: Tumor infiltrate analysis from the PRINCEPS trial","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-7766","source_url":"https://doi.org/10.1158/1538-7445.am2026-7766","status":"verified"}],"source":"congress"},"publications":{"total":19,"shown":5,"withheld":14,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42873584/","status":"verified"},{"title":"Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42440365/","status":"verified"},{"title":"Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41945500/","status":"verified"},{"title":"Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.","year":2026,"journal":"Future oncology (London, England)","types":["Journal Article","Clinical Trial Protocol"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41777164/","status":"verified"},{"title":"First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?","year":2026,"journal":"Drugs","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41619151/","status":"verified"}],"source":"publications"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD, PhD","source_url":"https://www.onclive.com/authors/david-planchard-md-phd-institut-gustave-roussy","status":"provisional","collected_at":"2026-11-08"}]},"roles":{"total":2,"shown":2,"rows":[{"value":"President, International Center for Thoracic Cancers (CICT)","source_url":"https://www.universite-paris-saclay.fr/en/news/david-planchard-revolutionising-targeted-therapies-lung-cancer","status":"verified","collected_at":"2026-11-08"},{"value":"Head of the thoracic pathology committee, Gustave Roussy","source_url":"https://www.universite-paris-saclay.fr/actualites/highly-cited-researchers-2025-decouvrez-les-scientifiques-de-luniversite-paris-saclay-les-plus-cites-au-monde","status":"provisional","collected_at":"2026-11-08"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"Highly Cited Scientist (Clarivate), since 2020, annually","source_url":"https://www.universite-paris-saclay.fr/en/news/david-planchard-revolutionising-targeted-therapies-lung-cancer","status":"verified","collected_at":"2026-11-08"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"PMNCO research unit, Univ. Paris-Saclay / French National Institute of Health and Medical Research (Inserm) / Gustave Roussy","source_url":"https://www.universite-paris-saclay.fr/en/news/david-planchard-revolutionising-targeted-therapies-lung-cancer","status":"verified","collected_at":"2026-11-08"}]}},"similar":[{"name":"Benjamin Besse","slug":"benjamin-besse","institution":"Gustave Roussy","url":"https://www.findmykol.com/kol/benjamin-besse","json_url":"https://www.findmykol.com/kol/benjamin-besse/profile.json"},{"name":"Ignacio Wistuba","slug":"ignacio-wistuba","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ignacio-wistuba","json_url":"https://www.findmykol.com/kol/ignacio-wistuba/profile.json"},{"name":"Pasi Janne","slug":"pasi-janne","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/pasi-janne","json_url":"https://www.findmykol.com/kol/pasi-janne/profile.json"},{"name":"Julie Brahmer","slug":"julie-brahmer","institution":"Johns Hopkins University School of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/julie-brahmer","json_url":"https://www.findmykol.com/kol/julie-brahmer/profile.json"},{"name":"Enriqueta Felip","slug":"enriqueta-felip","institution":"Vall d'Hebron Institute of Oncology (VHIO)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/enriqueta-felip","json_url":"https://www.findmykol.com/kol/enriqueta-felip/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":6,"congress":237,"publications":14}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-08"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-08"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-08"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-08"}},"methodology_url":"https://www.findmykol.com/about#methodology"}